Trials / Completed
CompletedNCT04094363
CSD190202: Study to Assess Elements of Abuse Liability for Two Electronic Nicotine Delivery Systems
CSD190202: A Randomized, Open-Label, Crossover Study to Assess Elements of Abuse Liability for Two Electronic Nicotine Delivery Systems
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 50 (actual)
- Sponsor
- RAI Services Company · Industry
- Sex
- All
- Age
- 21 Years – 60 Years
- Healthy volunteers
- Accepted
Summary
This is a randomized, open-label, crossover study designed to evaluate elements of abuse liability (AL) including subjective effects, plasma nicotine uptake, and physiological measures during and following ad libitum use of the investigational products (IPs) by healthy subjects.
Detailed description
The study will recruit smokers of combustible cigarettes. Potential subjects will complete a pre-screening interview and a Screening Visit to assess their eligibility within 45 days prior to enrollment. Starting on Day 1, eligible smokers will be confined at the clinical site for 9 days. Subjects will participate in four separate Test Sessions for AL assessment, one for each IP. Each Test Session will last for approximately 4 hours during and following IP use. Subjects will be randomized to use one IP in each Test Session: Usual Brand (UB) combustible cigarettes, nicotine gum, and 2 Electronic Nicotine Delivery Systems (ENDS). For approximately a day and a half prior to each respective Test Session, IP will be dispensed for ad libitum use for product familiarization.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Product A | Usual Brand, filtered combustible cigarette |
| OTHER | Product B | CSD1902-11, an electronic nicotine delivery system |
| OTHER | Product C | CSD1902-21, an electronic nicotine delivery system |
| OTHER | Product D | 4mg Nicotine gum |
Timeline
- Start date
- 2019-10-03
- Primary completion
- 2019-11-26
- Completion
- 2019-11-26
- First posted
- 2019-09-18
- Last updated
- 2022-06-27
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT04094363. Inclusion in this directory is not an endorsement.